Amy Carr
YOU?
Author Swipe
View article: Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study Open
Background Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomon…
View article: P-1469. Clinical Impact of Adherence to an Institutional Guideline for Multi-Drug Resistant Gram-Negative Infections
P-1469. Clinical Impact of Adherence to an Institutional Guideline for Multi-Drug Resistant Gram-Negative Infections Open
Background After publication of the IDSA Guidance on the Treatment of Antimicrobial Resistance Gram-Negative Infections, AdventHealth Central Florida implemented institutional pathways for treating MDR Gram Negative Infections. This study …
View article: P-1500. Evaluation of Imipenem-cilastatin-relebactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
P-1500. Evaluation of Imipenem-cilastatin-relebactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> Open
Background The escalating prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa presents a serious threat to patient care due to its limited treatment options. However, imipenem-cilastatin-relebactam (IMI/REL) is a promising beta-…
View article: Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing
Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing Open
Sequencing of plasma microbial cell-free DNA (mcfDNA) has gained increased acceptance as a valuable adjunct to standard-of-care testing for diagnosis of infections throughout the body. Here, we report the analytical and clinical validation…
View article: Enhancing clinical genomic accuracy with panelGC: a novel metric and tool for quantifying and monitoring GC biases in hybridization capture panel sequencing
Enhancing clinical genomic accuracy with panelGC: a novel metric and tool for quantifying and monitoring GC biases in hybridization capture panel sequencing Open
Accurate assessment of fragment abundance within a genome is crucial in clinical genomics applications such as the analysis of copy number variation (CNV). However, this task is often hindered by biased coverage in regions with varying gua…
View article: Analytical and Clinical Validation of Direct Detection of Antimicrobial Resistance Markers by Plasma Microbial Cell-free DNA Sequencing
Analytical and Clinical Validation of Direct Detection of Antimicrobial Resistance Markers by Plasma Microbial Cell-free DNA Sequencing Open
Sequencing of plasma microbial cell-free DNA (mcfDNA) has gained increased acceptance as a valuable adjunct to standard-of-care testing for diagnosis of infections throughout the body. Here we report the analytical and clinical validation …
View article: A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2022
A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2022 Open
Keeping abreast of the antimicrobial stewardship–related articles published each year is challenging. The Southeastern Research Group Endeavor identified antimicrobial stewardship–related, peer-reviewed literature that detailed an actionab…
View article: 925. Remdesperate for Stewardship: Impact of a Remdesivir Stewardship Strategy on the Care of Patients with COVID-19 Admitted to a Community Teaching Hospital
925. Remdesperate for Stewardship: Impact of a Remdesivir Stewardship Strategy on the Care of Patients with COVID-19 Admitted to a Community Teaching Hospital Open
Background The use of remdesivir (RDV) in patients hospitalized with COVID-19 has resulted in a significantly shorter time to recovery, especially in patients receiving low flow oxygen. Despite the shortened time to recovery, concerns have…
View article: 919. Let’s GO PO: Impact of Monthly Feedback on a Longitudinal Intravenous to Oral Antimicrobial Conversion Initiative
919. Let’s GO PO: Impact of Monthly Feedback on a Longitudinal Intravenous to Oral Antimicrobial Conversion Initiative Open
Background Timely conversion of antimicrobials from intravenous (IV) to oral (PO) route has been shown to decrease costs and length of stay (LOS) without compromising safety and efficacy of therapy. Use of oral antimicrobials may additiona…
View article: 666. Outcomes Using Cefiderocol for the Treatment of <i>Acinetobacter baumannii</i> Infections from the PROVE (Real-World Evidence) Study
666. Outcomes Using Cefiderocol for the Treatment of <i>Acinetobacter baumannii</i> Infections from the PROVE (Real-World Evidence) Study Open
Background PROVE is an ongoing international, retrospective study assessing cefiderocol (CFDC) for Gram-negative (GN) infections. Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are difficult-to-treat with limited treatment …
View article: 1005. Financial and clinical impact of ceftolozane/tazobactam global recall on the treatment of multi-drug resistant <i>Pseudomonas</i> in a large health system
1005. Financial and clinical impact of ceftolozane/tazobactam global recall on the treatment of multi-drug resistant <i>Pseudomonas</i> in a large health system Open
Background In December 2020, ceftolozane/tazobactam (CT) was voluntarily recalled due to failed sterility tests. With this recall, clinicians were forced to utilize alternatives for multi-drug resistant (MDR) Pseudomonas (PSA) infections u…
View article: 181. Impact of Rapid Diagnostic Technology on Patients with Candidemia
181. Impact of Rapid Diagnostic Technology on Patients with Candidemia Open
Background Candida spp. are the fourth most common cause of bloodstream infections (BSI) in the United States and have an associated mortality rate of 19-40.5%. Mortality rates are further impacted by delay in time to adequate antifungal t…
View article: 667. Real-world Experience of Cefiderocol with <i>Pseudomonas aeruginosa</i> in the PROVE (Retrospective Cefiderocol Chart Review) Study
667. Real-world Experience of Cefiderocol with <i>Pseudomonas aeruginosa</i> in the PROVE (Retrospective Cefiderocol Chart Review) Study Open
Background Gram-negative (GN) bacterial resistance is an urgent global health problem. Cefiderocol (CFDC) is active against many resistant GN pathogens, including Pseudomonas aeruginosa (PA). PROVE is an ongoing international, retrospectiv…
View article: Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury
Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury Open
It has been established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses angiotensin-converting enzyme 2 (ACE2), a membrane-bound regulatory peptide, for host cell entry. Renin-angiotensin-aldosterone system (RAAS) in…
View article: ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida Open
Background Observational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the cl…
View article: Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections Open
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurr…
View article: 1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant <i>Pseudomonas aeruginosa</i>
1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant <i>Pseudomonas aeruginosa</i> Open
Background The activity of imipenem/relebactam (I/R), ceftazidime/avibactam (CZA) and cefiderocol (FDC) were evaluated against clinical isolates of multidrug resistant (MDR) strains of P. aeruginosa which was resistant to ceftolozane/tazob…
View article: 1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections
1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections Open
Background Eravacycline (ERV) is a next-generation tetracycline approved for complicated intra-abdominal infections (cIAI) with in-vitro activity to multidrug-resistant organisms such as carbapenem resistant Enterobacteriaceae, extended sp…
View article: 1615. Isolation of Lytic Bacteriophages with Broad Host Range Activity Against <i>Pseudomonas aeruginosa</i> Strains Isolated from Respiratory Samples from Cystic Fibrosis Patients Intended for Therapeutic Application
1615. Isolation of Lytic Bacteriophages with Broad Host Range Activity Against <i>Pseudomonas aeruginosa</i> Strains Isolated from Respiratory Samples from Cystic Fibrosis Patients Intended for Therapeutic Application Open
Background With the rise of the antimicrobial resistance between different genera and species of bacteria, Phage Therapy is becoming a more realistic and accessible option for patients with limited or no antimicrobial options. Being able t…
View article: 1607. Dual Therapy with Aztreonam & Ceftazidime/Avibactam Against Multi-Drug Resistant <i>Stenotrophomonas maltophilia</i> on Tricuspid Valve Endocarditis
1607. Dual Therapy with Aztreonam & Ceftazidime/Avibactam Against Multi-Drug Resistant <i>Stenotrophomonas maltophilia</i> on Tricuspid Valve Endocarditis Open
Background Antimicrobial resistance in Stenotrophomonas maltophilia is one of the most complex among Gram-negatives. Presence of regulating non-specific antimicrobial class efflux pumps and chromosomal encoded L1 metallo-betalactamase (Amb…
View article: 649. Clinical Implementation of a Rapid Susceptibility Testing Procedure, Directly From a Positive Blood Culture Using the Vitek®2 System on Gram Negative Rods
649. Clinical Implementation of a Rapid Susceptibility Testing Procedure, Directly From a Positive Blood Culture Using the Vitek®2 System on Gram Negative Rods Open
Background The national average of identification and susceptibility for organisms isolated from positive blood culture to final susceptibility based on growth on solid media is 48 hours. The goal of this research was to prove that the Vit…
View article: 1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better?
1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better? Open
Background Carbapenem-resistant organisms (CROs) represent an urgent public health threat and associated with mortality rates up to 60%. Pharmacotherapy for these infections remain challenging and historically included multiple agents. Mer…
View article: ICU Outcomes and Survival in Patients with Severe COVID-19 in the Largest Health Care System in Central Florida
ICU Outcomes and Survival in Patients with Severe COVID-19 in the Largest Health Care System in Central Florida Open
Background Observational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the cl…
View article: 2275. Novel Therapeutic Options for the Treatment of Multi-Drug-Resistant Achromobacter Respiratory Infections
2275. Novel Therapeutic Options for the Treatment of Multi-Drug-Resistant Achromobacter Respiratory Infections Open
Background Respiratory infection due to Achromobacter species has been increasingly more common, especially in patients with cystic fibrosis (CF). Recurrent infections in these patients contribute to significant morbidity and mortality as …
View article: 1801. Impact of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) on Clinical Outcomes in Patients with Gram Positive Blood Cultures in a Diverse, Multicenter Healthcare System With a Central Laboratory
1801. Impact of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) on Clinical Outcomes in Patients with Gram Positive Blood Cultures in a Diverse, Multicenter Healthcare System With a Central Laboratory Open
BACKGROUND: Rapid diagnostic testing in combination with real-time antimicrobial stewardship intervention can reduce time to de-escalation of empiric antibiotics and discontinuation of unnecessary therapy. This study aims to evaluate the c…
View article: Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin
Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin Open
Numerous risk factors have been linked to invasive candidiasis; however, they are nonspecific and often trigger empiric antifungal therapy in a large number of patients. Identification of more precise predictors could promote judicious use…
View article: Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin
Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin Open
Background Numerous risk factors have been linked to invasive candidiasis; however, they are nonspecific and often trigger empiric antifungal therapy in a large number of patients. Identification of more precise predictors could promote ju…